Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

Barron's market reporter Jacob Sonenshine breaks down the market as the Fed meeting kicks off and spotlights pharmaceutical company Merck.

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...

Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...